Clinical Trial Update: A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating GC1102, a recombinant hepatitis B immunoglobulin, in hepatitis B-related liver transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• GC1102 (Hepatitis B immunoglobulin, recombinant)

Snippet

Sponsor: Green Cross Corporation | Conditions: Hepatitis B Infection | Phase 2 | Status: COMPLETED